Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 89,398 shares, an increase of 78.9% from the August 15th total of 49,958 shares. Based on an average daily trading volume, of 87,927 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.3% of the company’s shares are short sold.

Dogwood Therapeutics Price Performance

Shares of NASDAQ:DWTX traded down $0.03 during trading on Wednesday, reaching $1.70. 84,275 shares of the stock were exchanged, compared to its average volume of 77,281. Dogwood Therapeutics has a 1-year low of $1.28 and a 1-year high of $9.50. The stock has a fifty day moving average of $1.90 and a two-hundred day moving average of $1.93. The firm has a market cap of $57.79 million, a price-to-earnings ratio of -0.19 and a beta of 1.81.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.20). Sell-side analysts forecast that Dogwood Therapeutics will post -0.67 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DWTX. HC Wainwright reiterated a “buy” rating on shares of Dogwood Therapeutics in a research note on Wednesday, September 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Friday, July 24th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.